European equities traded in the US as American depositary receipts were little changed late Friday morning, edging 0.07% higher to 1,689.69 on the S&P Europe Select ADR Index, which has risen 2% for the week.

From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and biotech firm Evaxion (EVAX), which advanced 5.3% and 0.6% respectively. They were followed by biopharmaceutical company Grifols (GRFS) and brewing company Anheuser-Busch InBev (BUD), which were up 0.4% each.

The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and furniture manufacturer Natuzzi (NTZ), which fell 2.3% and 1.6% respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND) and accommodations booking site trivago (TRVG), which were down 1.5% and 1.4% respectively.

From the UK and Ireland, the gainers were led by mining company BHP Group (BHP) and biopharmaceutical company Amarin (AMRN), which rose 1.5% and 0.8% respectively. They were followed by pharmaceutical company AstraZeneca (AZN) and medical device maker Smith & Nephew (SNN), which increased 0.4% and 0.3% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and NuCana (NCNA), which dropped 5.3% and 4.2% respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and cruise line operator Carnival (CUK), which lost 2.9% and 1.5% respectively.